The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.

Loss of income and out-of-pocket expenditures are important causes of financial hardship in many patients with cancer, even in high-income countries. The far-reaching consequences extend beyond the patients themselves to their relatives, including caregivers and dependents. European research to date has been limited and is hampered by the absence of a coherent theoretical framework and by heterogeneous methods and terminology. To address these shortages, a task force initiated by the Organisation of European Cancer Institutes (OECI) produced 25 recommendations, including a comprehensive definition of socioeconomic impact from the perspective of patients and their relatives, a conceptual framework, and a consistent taxonomy linked to the framework. The OECI task force consensus statement highlights directions for future research with a view towards policy relevance. Beyond descriptive studies into the dimension of the problem, individual severity and predictors of vulnerability should be explored. It is anticipated that the consensus recommendations will facilitate and enhance future research efforts into the socioeconomic impact of cancer and cancer care, providing a crucial reference point for the development and validation of patient-reported outcome instruments aimed at measuring its broader effects.
Competing Interests: Declaration of interests WvH reports grants from Koningin Wilhelmina Fonds (KWF), European Cancer League for European Fair Pricing Network (EFPN) project, and OECI; and consulting fees from Raad voor de Rechtspraak. VPR reports grants from KWF, EFPN, OECI, and the National Health Care Institute. JMV reports grants from EFPN. OSL reports support for attending meetings and travel from the Catalan Institute of Oncology (ICO). EA reports a grant from the Norwegian Directorate of Health; and leadership roles on the scientific board of the Norwegian Cancer Association, the advisory board of the Frisch Centre, and the Faculty of Medicine board elected among academic employees. AE reports support for attending meetings and travel from ICO. NF reports support for the present manuscript and for attending meetings from EFPN and OECI; and a budget-based action grant from EU HORIZON. IK reports a leadership role as a patient advocate at the Institute for Gastroenterological Tumors of Croatia (IGET). SS reports a leadership role at Connect Norway. RS is supported by City Cancer Challenge. SV reports a leadership role at IGET. All other authors declare no competing interests.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)